chr6-131708917-T-C

Variant summary

Our verdict is Benign. The variant received -8 ACMG points: 0P and 8B. BP4_StrongBS2

The NM_001145659.1(CTAGE9):​c.2101A>G​(p.Ile701Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000532 in 1,605,820 control chromosomes in the GnomAD database, including 10 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: 𝑓 0.00054 ( 1 hom., cov: 22)
Exomes 𝑓: 0.00053 ( 9 hom. )

Consequence

CTAGE9
NM_001145659.1 missense

Scores

2
17

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: -0.250

Publications

8 publications found
Variant links:
Genes affected
CTAGE9 (HGNC:37275): (CTAGE family member 9) Predicted to be involved in endoplasmic reticulum to Golgi vesicle-mediated transport; protein secretion; and vesicle cargo loading. Predicted to be integral component of membrane. Predicted to be active in endoplasmic reticulum exit site and endoplasmic reticulum membrane. [provided by Alliance of Genome Resources, Apr 2022]
ENPP3 (HGNC:3358): (ectonucleotide pyrophosphatase/phosphodiesterase 3) The protein encoded by this gene belongs to a series of ectoenzymes that are involved in hydrolysis of extracellular nucleotides. These ectoenzymes possess ATPase and ATP pyrophosphatase activities and are type II transmembrane proteins. Expression of the related rat mRNA has been found in a subset of immature glial cells and in the alimentary tract. The corresponding rat protein has been detected in the pancreas, small intestine, colon, and liver. The human mRNA is expressed in glioma cells, prostate, and uterus. Expression of the human protein has been detected in uterus, basophils, and mast cells. Two transcript variants, one protein coding and the other non-protein coding, have been found for this gene. [provided by RefSeq, Oct 2015]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -8 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.015788108).
BS2
High Homozygotes in GnomAdExome4 at 9 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CTAGE9NM_001145659.1 linkc.2101A>G p.Ile701Val missense_variant Exon 1 of 1 ENST00000314099.10 NP_001139131.1 A4FU28
ENPP3NM_005021.5 linkc.1413-9755T>C intron_variant Intron 15 of 24 ENST00000357639.8 NP_005012.2 O14638

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CTAGE9ENST00000314099.10 linkc.2101A>G p.Ile701Val missense_variant Exon 1 of 1 6 NM_001145659.1 ENSP00000395587.2 A4FU28
ENPP3ENST00000357639.8 linkc.1413-9755T>C intron_variant Intron 15 of 24 1 NM_005021.5 ENSP00000350265.3 O14638
ENPP3ENST00000414305.5 linkc.1413-9755T>C intron_variant Intron 16 of 25 1 ENSP00000406261.1 O14638
ENPP3ENST00000358229.6 linkc.1413-9755T>C intron_variant Intron 15 of 23 1 ENSP00000350964.5 F8W6H5

Frequencies

GnomAD3 genomes
AF:
0.000537
AC:
78
AN:
145262
Hom.:
1
Cov.:
22
show subpopulations
Gnomad AFR
AF:
0.000496
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000878
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000430
Gnomad FIN
AF:
0.0000953
Gnomad MID
AF:
0.00323
Gnomad NFE
AF:
0.000609
Gnomad OTH
AF:
0.000999
GnomAD2 exomes
AF:
0.000368
AC:
91
AN:
247586
AF XY:
0.000364
show subpopulations
Gnomad AFR exome
AF:
0.000627
Gnomad AMR exome
AF:
0.000376
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000571
Gnomad OTH exome
AF:
0.000496
GnomAD4 exome
AF:
0.000531
AC:
776
AN:
1460450
Hom.:
9
Cov.:
34
AF XY:
0.000484
AC XY:
352
AN XY:
726566
show subpopulations
African (AFR)
AF:
0.000399
AC:
13
AN:
32608
American (AMR)
AF:
0.000515
AC:
23
AN:
44692
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26124
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39694
South Asian (SAS)
AF:
0.000290
AC:
25
AN:
86194
European-Finnish (FIN)
AF:
0.0000187
AC:
1
AN:
53416
Middle Eastern (MID)
AF:
0.000871
AC:
5
AN:
5738
European-Non Finnish (NFE)
AF:
0.000608
AC:
676
AN:
1111684
Other (OTH)
AF:
0.000531
AC:
32
AN:
60300
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.479
Heterozygous variant carriers
0
57
114
172
229
286
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
26
52
78
104
130
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000537
AC:
78
AN:
145370
Hom.:
1
Cov.:
22
AF XY:
0.000464
AC XY:
33
AN XY:
71050
show subpopulations
African (AFR)
AF:
0.000494
AC:
18
AN:
36406
American (AMR)
AF:
0.000877
AC:
13
AN:
14818
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3418
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5008
South Asian (SAS)
AF:
0.000431
AC:
2
AN:
4644
European-Finnish (FIN)
AF:
0.0000953
AC:
1
AN:
10494
Middle Eastern (MID)
AF:
0.00347
AC:
1
AN:
288
European-Non Finnish (NFE)
AF:
0.000609
AC:
41
AN:
67362
Other (OTH)
AF:
0.000988
AC:
2
AN:
2024
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.471
Heterozygous variant carriers
0
3
7
10
14
17
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000395
Hom.:
0
ExAC
AF:
0.000327
AC:
39

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not specified Uncertain:1
Aug 20, 2024
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.2101A>G (p.I701V) alteration is located in exon 1 (coding exon 1) of the CTAGE9 gene. This alteration results from a A to G substitution at nucleotide position 2101, causing the isoleucine (I) at amino acid position 701 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.069
BayesDel_addAF
Benign
-0.66
T
BayesDel_noAF
Benign
-0.83
CADD
Benign
0.93
DANN
Benign
0.46
DEOGEN2
Benign
0.00035
T
Eigen
Benign
-0.92
Eigen_PC
Benign
-0.88
FATHMM_MKL
Benign
0.0023
N
LIST_S2
Benign
0.41
T
M_CAP
Uncertain
0.085
D
MetaRNN
Benign
0.016
T
MetaSVM
Benign
-0.91
T
MutationAssessor
Benign
0.80
N
PhyloP100
-0.25
PrimateAI
Uncertain
0.56
T
PROVEAN
Benign
-0.030
N
REVEL
Benign
0.031
Sift
Benign
0.82
T
Sift4G
Benign
0.88
T
Polyphen
0.0010
B
Vest4
0.023
MVP
0.014
ClinPred
0.0049
T
Varity_R
0.34
gMVP
0.044
Mutation Taster
=96/4
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.020
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs77624986; hg19: chr6-132030057; COSMIC: COSV58418112; API